eJHaem
(Feb 2023)
Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)
Hiroki Mizumaki,
Ken Ishiyama,
Jun Aoki,
Jinichi Mori,
Shohei Mizuno,
Noriko Doki,
Takahiro Fukuda,
Naoyuki Uchida,
Masahito Onizuka,
Masatsugu Tanaka,
Yuta Katayama,
Yukiyasu Ozawa,
Kazuhiro Ikegame,
Satoru Takada,
Toshiro Kawakita,
Nobuyuki Aotsuka,
Yoshiko Atsuta,
Masamitsu Yanada
Affiliations
Hiroki Mizumaki
Department of Hematology Kanazawa University Hospital Kanazawa Japan
Ken Ishiyama
Department of Hematology Kanazawa University Hospital Kanazawa Japan
Jun Aoki
Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan
Jinichi Mori
Department of Hematology Jyoban Hospital of Tokiwa Foundation Fukushima Japan
Shohei Mizuno
Division of Hematology Department of Internal Medicine Aichi Medical University Nagakute Japan
Noriko Doki
Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan
Takahiro Fukuda
Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan
Naoyuki Uchida
Department of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan
Masahito Onizuka
Department of Hematology and Oncology Tokai University School of Medicine Isehara Japan
Masatsugu Tanaka
Department of Hematology Kanagawa Cancer Center Yokohama Japan
Yuta Katayama
Department of Hematology Hiroshima Red Cross Hospital and Atomic‐bomb Survivors Hospital Hiroshima Japan
Yukiyasu Ozawa
Department of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan
Kazuhiro Ikegame
Department of Hematology Hyogo Medical University Hospital Hyogo Japan
Satoru Takada
Leukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan
Toshiro Kawakita
Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan
Nobuyuki Aotsuka
Division of Hematology‐Oncology Japanese Red Cross Society Narita Hospital Narita Japan
Yoshiko Atsuta
Japanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan
Masamitsu Yanada
Department of Hematology and Cell Therapy Aichi Cancer Center Nagoya Japan
DOI
https://doi.org/10.1002/jha2.609
Journal volume & issue
Vol. 4,
no. 1
Abstract
Read online
Abstract The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo‐SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (‐7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the ‐7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo‐SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).
Keywords
WeChat QR code
Close
